Catalyst
Slingshot members are tracking this event:
MedImmune, a research and development arm of AstraZeneca (AZN), agrees to partner with Sanofi (SNY) to develop anti-respiratory syncytial virus (RSV) prevention treatment MEDI8897
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 03, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Medimmune, Anti-resperatory Syncytial Virus, Rsv, Medi8897
